Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

179.25 -2.82 (-1.55%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs

February 24, 2026

NEW YORK — After years of living in the shadow of trillion-dollar tech titans, the "little guys" of the stock market are finally having their day in the sun. As of February 24, 2026, the financial...

Via MarketMinute

Topics Economy Initial Public Offering

Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

February 24, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock ↗

February 23, 2026

TD Cowen analyst Joseph Thome’s new price target represents a potential upside of about 23% from AXSM’s current trading levels.

Via Stocktwits

Topics Artificial Intelligence

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Loss ↗

February 23, 2026

Via Chartmill

AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗

January 12, 2026

Via Chartmill

Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad

February 23, 2026

As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Axsome (AXSM) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Axsome (AXSM) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 23, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036 ↗

February 22, 2026

The biotech is slowly rising in prominence.

Via The Motley Fool

Topics Intellectual Property

Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

February 17, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗

February 05, 2026

The healthcare company is set to release its fourth-quarter results later this month.

Via The Motley Fool

1 High-Flying Stock With More Upside Ahead ↗

February 03, 2026

Are we witnessing the birth of a biotech giant?

Via The Motley Fool

Topics Intellectual Property

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

January 27, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗

January 16, 2026

Piper Sandler kept an ‘Overweight’ rating on Axsome Therapeutics’ shares, and raised the price target to $223 from $148.

Via Stocktwits

Topics Artificial Intelligence

Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

January 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

January 12, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗

January 08, 2026

Via MarketBeat

2 Healthcare Stocks to Buy for 2026 and Beyond ↗

January 08, 2026

These could be the next biotech giants.

Via The Motley Fool

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...

Via MarketMinute

Here are the top movers in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗

December 31, 2025

Axsome Therapeutics shareholders got a New Year's gift from the FDA.

Via The Motley Fool

The market is filled with gapping stocks in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗

December 31, 2025

AXS-12 is being developed to treat cataplexy in narcolepsy by targeting norepinephrine and dopamine activity in the brain.

Via Stocktwits

Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

December 31, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

December 31, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗

December 01, 2025

These drugmakers are poised to profit from their innovative engines.

Via The Motley Fool

Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Axsome (AXSM) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.